[{"id":"4f4288df-695a-47f7-a6a0-96528472a3aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT00321555","created_at":"2021-01-18T01:06:25.835Z","updated_at":"2024-07-02T16:35:29.257Z","phase":"Phase 2","brief_title":"LMB-2 to Treat Hairy Cell Leukemia","source_id_and_acronym":"NCT00321555","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" IL2RA positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-2"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/02/2006","start_date":" 05/02/2006","primary_txt":" Primary completion: 08/24/2016","primary_completion_date":" 08/24/2016","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-11-14"},{"id":"8812c060-335b-47a4-a245-7497912ecdcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00080535","created_at":"2021-01-18T00:13:21.794Z","updated_at":"2024-07-02T16:37:14.422Z","phase":"Phase 2","brief_title":"Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas","source_id_and_acronym":"NCT00080535","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL2RA","pipe":" | ","alterations":" IL2RA expression","tags":["IL2RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-2"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/30/2004","start_date":" 04/30/2004","primary_txt":" Primary completion: 12/31/2011","primary_completion_date":" 12/31/2011","study_txt":" Completion: 12/31/2011","study_completion_date":" 12/31/2011","last_update_posted":"2018-01-29"}]